News & Analysis on Clinical Trial Services & Contract Research And Development
Isis Pharmaceuticals and Rosetta Genomics has announced a joint research collaboration to develop microRNA related therapies for the treatment of liver cancer, demonstrating the therapeutic potential of microRNA as a drug target using antisense.
Graffinity, announced today that it has entered into its second research collaboration with Mutabilis, which aims to discover novel therapeutics for infectious diseases, building on 2003's collaboration focusing on another anti-infective drug target.
An experimental TB drug has proved effective against multi drug-resistant forms of the disease as well as becoming the first compound to treat the latent stage of this disease, which affects nearly a third of the world's population, of which...
In order to stay competitive, Wyeth looks to model its business not on that of other pharma companies, but of other successful big industries, which includes outsourcing or off-shoring anything that is not a core function.
Rigel has completed the Phase I stage of its drug interaction study in patients with rheumatoid arthritis. The oral syk kinase inhibitor could be an improvement over current treatment options, which have side effects that include gastrointestinal...
Celera Genomics has announced that Abbott has selected two additional cancer targets for further development, which brings the total of targets to four under investigation as a result of the collaboration between the companies to discover and...